IntelliPharmaCeutics International (TSXV:IPCI) Liabilities-to-Assets : 9.22 (As of Aug. 2023)

IntelliPharmaCeutics International Liabilities-to-Assets Chart

IntelliPharmaCeutics International Annual Data
	Trend	Nov13	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22
Liabilities-to-Assets		Get a 7-Day Free Trial					0.64	1.97	2.86	4.89	8.39

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Liabilities-to-Assets	Get a 7-Day Free Trial															8.07	8.39	7.85	7.33	9.22

Competitive Comparison of IntelliPharmaCeutics International's Liabilities-to-Assets

For the Biotechnology subindustry, IntelliPharmaCeutics International's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Liabilities-to-Assets falls into.

IntelliPharmaCeutics International Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

IntelliPharmaCeutics International's Liabilities-to-Assets Ratio for the fiscal year that ended in Nov. 2022 is calculated as:

IntelliPharmaCeutics International's Liabilities-to-Assets Ratio for the quarter that ended in Aug. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International  (TSXV:IPCI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

IntelliPharmaCeutics International Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description